Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment.

Autor:	Hoshimoto A; Department of Gastroenterology, Nippon Medical School, Tokyo 113-8603, Japan.; Department of Analytic Human Pathology, Nippon Medical School, Tokyo 113-8603, Japan., Tatsuguchi A; Department of Gastroenterology, Nippon Medical School, Tokyo 113-8603, Japan.; Department of Analytic Human Pathology, Nippon Medical School, Tokyo 113-8603, Japan. tachan@nms.ac.jp., Hamakubo R; Department of Gastroenterology, Nippon Medical School, Tokyo 113-8603, Japan., Nishimoto T; Department of Gastroenterology, Nippon Medical School, Tokyo 113-8603, Japan., Omori J; Department of Gastroenterology, Nippon Medical School, Tokyo 113-8603, Japan., Akimoto N; Department of Gastroenterology, Nippon Medical School, Tokyo 113-8603, Japan., Tanaka S; Department of Gastroenterology, Nippon Medical School, Tokyo 113-8603, Japan., Fujimori S; Department of Gastroenterology, Nippon Medical School, Tokyo 113-8603, Japan., Hatori T; Department of Pathology, Nippon Medical School, Chiba Hokusoh Hospital, Chiba 270-1694, Japan., Shimizu A; Department of Analytic Human Pathology, Nippon Medical School, Tokyo 113-8603, Japan., Iwakiri K; Department of Gastroenterology, Nippon Medical School, Tokyo 113-8603, Japan.
Jazyk:	angličtina
Zdroj:	World journal of gastroenterology [World J Gastroenterol] 2023 Oct 28; Vol. 29 (40), pp. 5566-5581.
DOI:	10.3748/wjg.v29.i40.5566
Abstrakt:	Background: Comprehensive genomic analysis has shown that small bowel adenocarcinoma (SBA) has different genomic profiles from gastric and colorectal cancers. Hence, it is essential to establish chemotherapeutic regimens based on SBA characteristics. The expression of programmed cell death-ligand 1 (PD-L1) and programmed cell death-ligand 2 (PD-L2) in SBA is not fully understood. Anti-PD-L1/PD-1 therapy uses tumor-infiltrating lymphocytes (TILs); therefore, the status of TILs in the tumor microenvironment (TME) may influence their efficacy. The ratio of FoxP3+ to CD8+ T cells has been reported to be useful in predicting the prognosis of digestive system cancers. Aim: To investigate the clinicopathological significance of PD-L1/2 expression according to the status of TILs in SBA tissues. Methods: We performed immunohistochemical analysis for PD-L1, PD-L2, CD8, FoxP3, and DNA mismatch repair (MMR) proteins using formalin-fixed, paraffin-embedded tissues from 50 patients diagnosed with primary SBA. The immunoreactivities of PD-L1 and PD-L2 were determined separately in tumor cells and tumor-infiltrating immune cells throughout the tumor center and invasive margins, and finally evaluated using the combined positive score (CPS). We assessed CD8+ and FoxP3+ T cells in the intratumoral and tumor-surrounding stroma. Subsequently, we calculated and summed the ratio of FoxP3 to CD8+ T cell counts. Immune-related cell densities were graded as low or high. Immunohistochemical results were compared with clinicopathological factors and patient prognosis. The distribution of cancer-specific survival (CSS) was estimated using the Kaplan-Meier method, and the log-rank test was used to test for significant differences in CSS. A Cox proportional hazard model was also used to assess the effect of tumor variables on CSS. Results: PD-L1 expression was positive in 34% in tumor cells (T-PD-L1) and 54% in tumor-infiltrating immune cells (I-PD-L1) of the cases examined. T-PD-L2 was positive in 34% and I-PD-L2 was positive in 42% of the cases. PD-L1 CPS ≥ 10 and PD-L2 CPS ≥ 10 were observed in 50% and 56% of the cases, respectively. Deficient MMR (dMMR) was 14% of the cases. T-PD-L1, I-PD-L1 and PD-L1 CPS ≥ 10 were all significantly associated with dMMR ( P = 0.037, P = 0.009, and P = 0.005, respectively). T-PD-L1, I-PD-L1, and PD-L1 CPS ≥ 10 were all associated with deeper depth of invasion ( P = 0.001, P = 0.024, and P = 0.002, respectively). I-PD-L2 expression and PD-L2 CPS ≥ 10 were significantly higher in the differentiated histological type ( P = 0.015 and P = 0.030, respectively). The I-PD-L1 and I-PD-L2 levels were significantly associated with better CSS ( P = 0.037 and P = 0.015, respectively). CD8-high was significantly associated with less lymph node metastasis ( P = 0.047), less distant metastasis ( P = 0.024), less peritoneal dissemination ( P = 0.034), and earlier TNM stage ( P = 0.047). The CD8-high group had better prognosis than the CD8-low group ( P = 0.018). FoxP3 expression was not associated with any clinicopathological factors or prognosis. We found that patients with PD-L2 CPS ≥ 10 tended to have worse prognosis in the FoxP3/CD8-low group ( P = 0.088). Conclusion: The clinicopathological significance of PD-L1/2 expression may differ depending on the TME status. Immune checkpoint inhibitors may improve the prognosis of SBA patients with low FoxP3/CD8 ratio and PD-L2 expression. Competing Interests: Conflict-of-interest statement: The authors declare no conflicts of interest. (©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu